Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
81pct
34d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Turn the Tide Act This bill funds through FY2023 the SUPPORT for Patients and Communities Act, which established various programs to address opioid addiction. Funded programs include (1) grants to increase access to substance use disorder treatments; (2) research, training, and developing best practices within the public health sector; (3) prevention and recovery services for youth, women, and infants; (4) overdose prevention and treatment; and (5) other community, judicial, and administrative programs. The bill also reauthorizes through FY2024 and increases funding for the Opioid State Targeted Response grants program and reauthorizes through FY2029 and increases funding for the Substance Abuse Prevention and Treatment Block Grant program. Further, the bill prohibits health insurance plans, including Medicaid, from requiring prior authorization for medication-assisted treatment for opioid addiction. Plans also must cover at least one overdose-reversing drug without any cost-sharing requirement. The bill also revises Medicaid to require state payments to providers of mental and behavioral health services for substance use disorders and extends funding for demonstration projects that link provider payments to certain metrics. The bill also targets loan repayments for substance use disorder treatment professionals to states with the highest rates of drug overdoses. Additionally, separate payment classifications must be established for specified procedures covered by Medicare that utilize non-opioid drugs to treat pain after surgery. The bill also (1) establishes grant programs to support responses to children exposed to trauma, (2) expands support for the drug-free communities program, and (3) funds peer-mentoring pilot programs for law enforcement agencies.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2020 · second_quarter · Disaster Planning/Emergencies
Lobbied FEMA on the implementation of the H.R. 4460/S.3041 the Disaster Relief and Recovery Act regarding architects' role in the post disaster relief effort. Lobbied on the Stronger, Healthier Environment for Low-Income Tenants and Economic Renewal (SHELTER) Act. S. 1958, H.R. 3462. Lobbied FEMA to share the AIA's Re-occupancy Assessment Tool with stakeholders. AIA submitted formal comments in response to the FEMA Proposed Policy: Hazard Mitigation Assistance: Building Resilient Infrastructure and Communities, Docket No. FEMA-2019-0018.
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, the Judiciary, Oversight and Reform, Education and Labor, and Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $220,000 · Firm income: Not reported
Government targets: Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Natl Institute of Standards & Technology (NIST), SENATE, Treasury, Dept of, White House Office
2020 · second_quarter · Disaster Planning/Emergencies
Lobbied FEMA on the implementation of the H.R. 4460/S. 3041 the Disaster Relief and Recovery Act regarding architects' role in the post disaster relief effort. Lobbied on the Stronger, Healthier Environment for Low-Income Tenants and Economic Renewal (SHELTER) Act. S. 1958, H.R. 3462. Lobbied FEMA to share the AIA's Re-occupancy Assessment Tool with shareholders. AIA submitted formal comments in response to the FEMA Proposed Policy: Hazard Mitigation Assistance: Building Resilient Infrastructure and Communities, Docket No. FEMA-2019-0018.
Client expense: Not reported · Firm income: $60,000
Government targets: Education, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Natl Institute of Standards & Technology (NIST), SENATE, Treasury, Dept of, White House Office
2020 · first_quarter · Disaster Planning/Emergencies
Lobbied FEMA on the implementation of the H.R. 4460/S. 3041 the Disaster Relief and Recovery Act regarding architects' role in the post disaster relief effort. Lobbied on the Stronger, Healthier Environment for Low-Income Tenants and Economic Renewal (SHELTER) Act. S. 1958, H.R. 3462.
Client expense: Not reported · Firm income: $60,000
Government targets: Education, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Natl Institute of Standards & Technology (NIST), SENATE, Treasury, Dept of, White House Office
2020 · first_quarter · Disaster Planning/Emergencies
Lobbied FEMA on the implementation of the H.R. 4460/S.3041 the Disaster Relief and Recovery Act regarding architects' role in the post disaster relief effort. Lobbied on the Stronger, Healthier Environment for Low-Income Tenants and Economic Renewal (SHELTER) Act. S. 1958, H.R. 3462.
Client expense: $260,000 · Firm income: Not reported
Government targets: Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Natl Institute of Standards & Technology (NIST), SENATE, Treasury, Dept of, White House Office
2019 · fourth_quarter · Pharmacy
S. 61, Safe and Affordable Drugs from Canada Act (Grassley) - drug importation S. 64, Preserve Access to Affordable Generics and Biosimilars Act (Grassley-Klobuchar) - prohibiting pay-for-delay settlements S. 73, End Taxpayer Subsidies for Drug Ads Act (Shaheen) - prohibiting tax deduction for DTC advertising expenses S. 102, Prescription Drug Price Relief Act (Sanders) - reforms linked to international pricing S. 340, CREATES Act (Leahy) - removing barriers to generic drugs S. 344, Hatch-Waxman Integrity Act (Tillis) - inter partes review process S. 366, FLAT Prices Act (Durbin) - reforms for drugs with sudden price spikes S. 378, Stop Price Gouging Act (Durbin) - excise tax for drugs that have price spikes S. 440, Preserving Access to Cost-Effective Drugs Act (Cotton) - sovereign immunity and Inter Partes Review process S. 474, SPIKE Act (Wyden) - justification for drug price increases S. 476, Creating Transparency to Have Drug Rebates Unlocked Act (Wyden) - drug price transparency S. 637, CURE High Drug Prices Act (Blumenthal) - remedies for price gouging S. 657, Point of Sale Rebates (Braun) S. 659, Biologic Patent Transparency Act (Collins) - patent disclosure requirements S. 660, Efficiency and Transparency in Petitions Act (Braun) - FDA citizen petition process S. 844, Short on Competition Act (Klobuchar) - remedies for marginally competitive drug markets S. 977, Transparency Drug Pricing Act (Scott) - transparency and drug pricing reforms S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act (Cassidy) - preventing evergreening of patent protections S. 1224, Stop STALLING Act (Klobuchar) - citizen petition process S. 1227, Prescription Pricing for the People Act (Grassley) - FTC report on role of PBMs and allegations of anticompetitive conduct by manufacturers of sole-source drugs S. 1384, Prescription Drug Rebate Reform Act (Romney-Braun) - prescription drug cost sharing S. 1416, Affordable Prescriptions for Patients Act (Cornyn) - product hopping, patent thickets S. 1664, Prescription Drug Price Reporting Act (Scott) - prescription drug price reporting S. 2247, Phair Relief Act of 2019 (Kennedy)-transparency around price concessions for drugs S. 2387, We Protect American Investment in Drugs Act (Van Hollen)-drug pricing S. 2543, Prescription Drug Pricing Reduction Act of 2019 (Grassley)-Drug pricing S. 2740, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 (Isakson) - regulations re nonprescription drugs that are marketed without an approved new drug application S. 3052, United States-Mexico-Canada Agreement Implementation Act (Grassley) - drug pricing S. 3067, Non-Opioids Prevent Addiction In the Nation Act (Capito) - non-opioid treatments S. 3092, Expanding Access to Low-Cost Generics Act of 2019 (Smith) - exclusivity period H.R. 3, Lower Drug Costs Now Act of 2019 (Pallone)-drug pricing H.R. 465, Prescription Drug Price Relief Act (Khanna) - reforms linked to international pricing H.R. 478, Safe and Affordable Drugs from Canada Act (Pingree) - drug importation H.R. 938, BLOCKING Act (Schrader) - changes to 180-day period of market exclusivity for first generic applicant H.R. 965, CREATES Act (Cicilline) - removing barriers to generic drugs H.R. 985, FAST Generics Act (Welch) - removing barriers to generic drugs H.R. 990, Hatch-Waxman Integrity Act (Flores) - inter partes review process H.R. 1093, Stop Price Gouging Act (Pocan) - excise tax for drugs that have price spikes H.R. 1188, FLAT Prices Act (Golden) - reforms for drugs with sudden price spikes H.R. 1344, Competitive DRUGS Act (Doggett) - prohibiting pay-for-delay agreements H.R. 1419, Public Option Deficit Reduction Act (DeFazio) - public option H.R. 1499, Protecting Consumer Access to Generic Drugs Act (Rush) - prohibiting pay-for-delay agreements H.R. 1503, Orange Book Transparency Act (Kelly) - removal of invalidated patents from Orange Book H.R. 1506, FAIR Generics Act (Barragan) - changes to 180-day period of market exclusivity for first generic applicant H.R. 1520, Purple Book Continuity Act (Eshoo) - access to updated information on biologics and biosimilars H.R. 2038, State-Based, Market-Oriented Prescription Drug Negotiations Act (Meadows) - drug price negotiations H.R. 2064, Sunshine for Samples Act (Chu) - reporting requirements on drug samples H.R. 2069, SPIKE Act (Horsford) -justification for drug price increases H.R. 2087, Drug Price Transparency Act (Doggett) - reporting of drug pricing data under Medicare Part B H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (Neal) - transparency in drug pricing H.R. 2115, Public Disclosure of Drug Discounts Act (Spanberger) - disclosure of negotiated Rx discounts H.R. 2279, Safe Step Act (Ruiz) - exceptions process for medication step therapy H.R. 2296, FAIR Drug Pricing Act (Schakowsky) - transparency requirements and justification for high list prices and drug price increases H.R. 2374, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (Jeffries) - citizen petition process H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act (Nadler) - prohibiting pay-for-delay agreements H.R. 2376, Prescription Pricing for the People Act (Collins) - FTC study on role of PBMs and competition and transparency in pharmaceutical supply chain H.R. 3379, Price Relief, Innovation, and Competition for Essential Drugs Act (Schakowsky) - exclusivity period for biological products H.R. 3805, Prescription Drug Rebate Reform Act of 2019 (Gallagher)- drug rebates H.R. 3927, PDMPs Help Patients Act of 2019 (McKinley)-integrating SUDs and behavioral health into PDMPs H.R. 3947, Competition Prescription Act of 2019 (Meadows)- drug pricing H.R. 4010, Emergency Access to Insulin Act of 2019 (Craig)- drug pricing H.R. 4106, Responsibility in Drug Advertising Act of 2019 (DeLauro)-transparency in drug pricing H.R. 4244, MAGIC Act (Kelly)-pathways for insulin approval H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 (Cicilline)-drug pricing H.R. 4455, BIOSIM Act (Schrader)-access to biosimilars H.R. 4460, Turn the Tide Act (Kuster)-Opioids H.R. 4538, Closing Loopholes for Orphan Drugs Act (Welch)-Access to drugs H.R. 4640, Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 (DeFazio) - direct negotiation H.R. 4712, Fairness in Orphan Drug Exclusivity Act (Dean) - limitations on exclusive approval of orphan drugs H.R. 4810, Opioid Prescription Verification Act of 2019 (David) - dispensing of controlled substances H.R. 4906, Insulin Price Reduction Act (Diana DeGette) - insulin costs H.R. 5304, PBM Transparency in Prescription Drug Costs Act (Schrader) - PBMs H.R. 5364, End Price Gouging for Insulin Act (Beatty) - annual reference price for insulin products H.R. 5430, United States-Mexico-Canada Agreement Implementation Act (Hoyer) - drug pricing H.R. 5442, Lowest Price for Patients Act (Porter) - pharmacies to disclose any differential between the cost of a prescription drug H.R. 5444, Lower Insulin Costs Now Act (Underwood) - lowering insulin costs H.Con.Res. 55, Expressing the sense of Congress on the need to inform American consumers with more balanced purchasing information for prescription drugs through the disclosure of price information in direct-to-consumer (DTC) advertisements. (Burgess)-drug pricing Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Client expense: $2,340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
2019 · fourth_quarter · Disaster Planning/Emergencies
FEMA- Community Planning and Capacity Building (CPCB) - ongoing post-disaster calls and convenings. Building Sciences - ongoing and various efforts including AIA's resilience education series, codes, MAT teams and report. Risk Management - worked with Mitigation Saves 2.0, survey information codes. Lobbied FEMA on the implementation of the H.R. 4460/S.3041 the Disaster Relief and Recovery Act regarding architects' role in the post disaster relief effort. Lobbied HR 3702. Reforming Disaster Recovery Act of 2019. the bill would authorize the Secretary of Housing and Urban Development to provide disaster assistance to States, Puerto Rico, units of general local government, and Indian tribes under a community development grant disaster recovery program, and for other purposes. Lobbied on the Stronger, Healthier Environment for Low-Income Tenants and Economic Renewal (SHELTER) Act. S. 1958, H.R. 3462.
Client expense: $560,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Labor, Dept of (DOL), Natl Institute of Standards & Technology (NIST), SENATE, State, Dept of (DOS), Treasury, Dept of, White House Office
2019 · third_quarter · Disaster Planning/Emergencies
Disaster Mitigation and building code adoption. Lobbied on flood insurance reauthorization. No bill number. Research about disaster relief grants. NIST - AIA particiapted on the NIST community resilience panel. FEMA- Community Planning and Capacity Building (CPCB) - ongoing post-disaster calls and convenings. Building Sciences - ongoing and various efforts including AIA's resilience education series, codes, MAT teams and report. Risk Management - worked with Mitigation Saves 2.0, survey information codes. Lobbied FEMA on the implementation of the H.R. 4460/S.3041 the Disaster Relief and Recovery Act regarding architects' role in the post disaster relief effort. Lobbied on HR 3462/S. 1958 the Shelter Act. Lobbied for inclusion of language regarding architects and disaster preparedness. Lobbied HR 3702. Reforming Disaster Recovery Act of 2019. the bill would authorize the Secretary of Housing and Urban Development to provide disaster assistance to States, Puerto Rico, units of general local government, and Indian tribes under a community development grant disaster recovery program, and for other purposes.
Client expense: $750,000 · Firm income: Not reported
2019 · third_quarter · Disaster Planning/Emergencies
Disaster Mitigation and building code adoption. Lobbied on flood insurance reauthorization. No bill number. Research about disaster relief grants. NIST - AIA particiapted on the NIST community resilience panel. FEMA- Community Planning and Capacity Building (CPCB) - ongoing post-disaster calls and convenings. Building Sciences - ongoing and various efforts including AIA's resilience education series, codes, MAT teams and report. Risk Management - worked with Mitigation Saves 2.0, survey information codes. Lobbied FEMA on the implementation of the H.R. 4460/S.3041 the Disaster Relief and Recovery Act regarding architects' role in the post disaster relief effort. Lobbied on HR 3462/S. 1958 the Shelter Act.
Client expense: $750,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Natl Institute of Standards & Technology (NIST), SENATE, State, Dept of (DOS), Treasury, Dept of, White House Office
2019 · third_quarter · Pharmacy
S. 61, Safe and Affordable Drugs from Canada Act (Grassley) - drug importation S. 64, Preserve Access to Affordable Generics and Biosimilars Act (Grassley-Klobuchar) - prohibiting pay-for-delay settlements S. 73, End Taxpayer Subsidies for Drug Ads Act (Shaheen) - prohibiting tax deduction for DTC advertising expenses S. 102, Prescription Drug Price Relief Act (Sanders) - reforms linked to international pricing S. 340, CREATES Act (Leahy) - removing barriers to generic drugs S. 344, Hatch-Waxman Integrity Act (Tillis) - inter partes review process S. 366, FLAT Prices Act (Durbin) - reforms for drugs with sudden price spikes S. 378, Stop Price Gouging Act (Durbin) - excise tax for drugs that have price spikes S. 440, Preserving Access to Cost-Effective Drugs Act (Cotton) - sovereign immunity and Inter Partes Review process S. 474, SPIKE Act (Wyden) - justification for drug price increases S. 476, Creating Transparency to Have Drug Rebates Unlocked Act (Wyden) - drug price transparency S. 637, CURE High Drug Prices Act (Blumenthal) - remedies for price gouging S. 657, Point of Sale Rebates (Braun) S. 659, Biologic Patent Transparency Act (Collins) - patent disclosure requirements S. 660, Efficiency and Transparency in Petitions Act (Braun) - FDA citizen petition process S. 844, Short on Competition Act (Klobuchar) - remedies for marginally competitive drug markets S. 977, Transparency Drug Pricing Act (Scott) - transparency and drug pricing reforms S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act (Cassidy) - preventing evergreening of patent protections S. 1224, Stop STALLING Act (Klobuchar) - citizen petition process S. 1227, Prescription Pricing for the People Act (Grassley) - FTC report on role of PBMs and allegations of anticompetitive conduct by manufacturers of sole-source drugs S. 1384, Prescription Drug Rebate Reform Act (Romney-Braun) - prescription drug cost sharing S. 1416, Affordable Prescriptions for Patients Act (Cornyn) - product hopping, patent thickets S. 1664, Prescription Drug Price Reporting Act (Scott) - prescription drug price reporting S. 2247, Phair Relief Act of 2019 (Kennedy)-transparency around price concessions for drugs S. 2387, We Protect American Investment in Drugs Act (Van Hollen)-drug pricing S. 2543, Prescription Drug Pricing Reduction Act of 2019 (Grassley)-Drug pricing H.R. 3, Lower Drug Costs Now Act of 2019 (Pallone)-drug pricing H.R. 465, Prescription Drug Price Relief Act (Khanna) - reforms linked to international pricing H.R. 478, Safe and Affordable Drugs from Canada Act (Pingree) - drug importation H.R. 938, BLOCKING Act (Schrader) - changes to 180-day period of market exclusivity for first generic applicant H.R. 965, CREATES Act (Cicilline) - removing barriers to generic drugs H.R. 985, FAST Generics Act (Welch) - removing barriers to generic drugs H.R. 990, Hatch-Waxman Integrity Act (Flores) - inter partes review process H.R. 1093, Stop Price Gouging Act (Pocan) - excise tax for drugs that have price spikes H.R. 1188, FLAT Prices Act (Golden) - reforms for drugs with sudden price spikes H.R. 1344, Competitive DRUGS Act (Doggett) - prohibiting pay-for-delay agreements H.R. 1419, Public Option Deficit Reduction Act (DeFazio) - public option H.R. 1499, Protecting Consumer Access to Generic Drugs Act (Rush) - prohibiting pay-for-delay agreements H.R. 1503, Orange Book Transparency Act (Kelly) - removal of invalidated patents from Orange Book H.R. 1506, FAIR Generics Act (Barragan) - changes to 180-day period of market exclusivity for first generic applicant H.R. 1520, Purple Book Continuity Act (Eshoo) - access to updated information on biologics and biosimilars H.R. 2038, State-Based, Market-Oriented Prescription Drug Negotiations Act (Meadows) - drug price negotiations H.R. 2064, Sunshine for Samples Act (Chu) - reporting requirements on drug samples H.R. 2069, SPIKE Act (Horsford) -justification for drug price increases H.R. 2087, Drug Price Transparency Act (Doggett) - reporting of drug pricing data under Medicare Part B H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (Neal) - transparency in drug pricing H.R. 2115, Public Disclosure of Drug Discounts Act (Spanberger) - disclosure of negotiated Rx discounts H.R. 2279, Safe Step Act (Ruiz) - exceptions process for medication step therapy H.R. 2296, FAIR Drug Pricing Act (Schakowsky) - transparency requirements and justification for high list prices and drug price increases H.R. 2374, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (Jeffries) - citizen petition process H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act (Nadler) - prohibiting pay-for-delay agreements H.R. 2376, Prescription Pricing for the People Act (Collins) - FTC study on role of PBMs and competition and transparency in pharmaceutical supply chain H.R. 3379, Price Relief, Innovation, and Competition for Essential Drugs Act (Schakowsky) - exclusivity period for biological products H.R. 3805, Prescription Drug Rebate Reform Act of 2019 (Gallagher)- drug rebates H.R. 3927, PDMPs Help Patients Act of 2019 (McKinley)-integrating SUDs and behavioral health into PDMPs H.R. 3947, Competition Prescription Act of 2019 (Meadows)- drug pricing H.R. 4010, Emergency Access to Insulin Act of 2019 (Craig)- drug pricing H.R. 4106, Responsibility in Drug Advertising Act of 2019 (DeLauro)-transparency in drug pricing H.R. 4244, MAGIC Act (Kelly)-pathways for insulin approval H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 (Cicilline)-drug pricing H.R. 4455, BIOSIM Act (Schrader)-access to biosimilars H.R. 4460, Turn the Tide Act (Kuster)-Opioids H.R. 4538, Closing Loopholes for Orphan Drugs Act (Welch)-Access to drugs H.Con.Res. 55, Expressing the sense of Congress on the need to inform American consumers with more balanced purchasing information for prescription drugs through the disclosure of price information in direct-to-consumer (DTC) advertisements. (Burgess)-drug pricing Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
2019 · second_quarter · Disaster Planning/Emergencies
Disaster Mitigation and building code adoption. Lobbied on flood insurance reauthorization. No bill number. Lobbied the Federal Insurance and Mitigation Administration (FIMA) within FEMA. Research about disaster relief grants. NIST - AIA particiapted on the NIST community resilience panel. FEMA- Community Planning and Capacity Building (CPCB) - ongoing post-disaster calls and convenings. Building Sciences - ongoing and various efforts including AIA's resilience education series, codes, MAT teams and report. Risk Management - worked with Mitigation Saves 2.0, survey information codes. Lobbied FEMA on the implementation of the H.R. 4460/S.3041 the Disaster Relief and Recovery Act regarding architects' role in the post disaster relief effort.
Client expense: $440,000 · Firm income: Not reported
Government targets: Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institute of Standards & Technology (NIST), Natl Park Service (NPS), SENATE, Treasury, Dept of
2019 · first_quarter · Disaster Planning/Emergencies
Disaster Mitigation and building code adoption. Lobbied on flood insurance reauthorization. No bill number. Lobbied the Federal Insurance and Mitigation Administration (FIMA) within FEMA. Research about disaster relief grants. NIST - AIA particiapted on the NIST community resilience panel. FEMA- Community Planning and Capacity Building (CPCB) - ongoing post-disaster calls and convenings. Building Sciences - ongoing and various efforts including AIA's resilience education series, codes, MAT teams and report. Risk Management - worked with Mitigation Saves 2.0, survey information codes. Lobbied FEMA on the implementation of the H.R. 4460/S.3041 the Disaster Relief and Recovery Act regarding architects' role in the post disaster relief effort.
Client expense: $420,000 · Firm income: Not reported
Government targets: Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Institute of Standards & Technology (NIST), Natl Park Service (NPS), SENATE, Treasury, Dept of
| Referred to |
| September 24, 2019 |
| Education and the Workforce Committee | House | Referred to | September 24, 2019 |
| Oversight and Accountability Committee | House | Referred to | September 24, 2019 |
Government targets: Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Labor, Dept of (DOL), Natl Institute of Standards & Technology (NIST), SENATE, State, Dept of (DOS), Treasury, Dept of, White House Office
Client expense: $2,110,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Treasury, Dept of, White House Office